Article Text

Download PDFPDF
The Use of Cisplatin to Treat Advanced-Stage Cervical Cancer During Pregnancy Allows Fetal Development and Prevents Cancer Progression: Report of a Case and Review of the Literature
  1. Angela Boyd, MBChB, DCH, DRCOG, MRCGP, MRCP,
  2. Valerie Cowie, MBChB, FRCR and
  3. Charlie Gourley, BSc, MBChB, PhD, FRCP
  1. From the Edinburgh Cancer Research Centre, Western General Hospital, Crewe Rd, Edinburgh, Scotland, UK.
  1. Address correspondence and reprint requests to Angela Boyd, University of Edinburgh Cancer Research Centre, Crewe Road South, Edinburgh, Scotland EH4 2XR, UK. E-mail: Angela.Boyd{at}


Background: Cervical cancer is one of the most frequently encountered malignancies in pregnancy. For early-stage disease arising in late second/third trimester, treatment may be delayed until delivery. However, in advanced disease, data are lacking.

Case: A 26-year-old woman presented at 21 weeks gestation with a stage IIB high-grade clear cell cervical carcinoma. At 25 + 1 weeks gestation, cisplatin 100 mg/m2 every 21 days was commenced. One month after cycle 3, a healthy infant was delivered. Thereafter, further cisplatin, intracavity cesium, and chemoradiation were administered. Findings from subsequent clinical examination and magnetic resonance imaging were normal. Fifteen months post treatment, both patient and baby remain well.

Conclusion: Neoadjuvant cisplatin chemotherapy can be used in stage IIB cervical carcinoma during pregnancy to allow fetal development and prevent disease progression before delivery.

  • Cervical carcinoma
  • Pregnancy
  • Cisplatin
  • Neoadjuvant chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Dr C. Gourley is supported by a Clinician Scientist Fellowship from National Health Service Education for Scotland and by the Charon Fund.